Screener
4D Molecular Therapeutics FDMT JP — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
FAQ
- What is 4D Molecular Therapeutics's JP — revenue?
- 4D Molecular Therapeutics (FDMT) reported JP — revenue of $2.96M in Q1 2026.
- What does JP — revenue mean?
- This metric represents the total gross income generated from the company's operations within the designated geographic or business segment. It reflects the commercial success and market penetration of the company's product portfolio, specifically including gene therapy candidates, within this specific region. Tracking this revenue stream is essential for evaluating the geographic diversification of the company's clinical-stage pipeline and its ability to monetize therapeutic assets in key markets.
Ask your AI about 4D Molecular Therapeutics's jp — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude